Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TXLNG2P
REST API REST API
Homo sapiens
TXLNG2P is differentially expressed in 118 experiments: 38 organism parts: adrenal gland cortex, liver, ... (36 more);, 44 disease states: normal, benign prostatic hyperplasia, ... (42 more);, 39 cell types 342 cell lines 4 compound treatments and 28 other conditions.
Synonyms CYorf15A, CYorf15B
Orthologs ENSGALG00000016547 (Gallus gallus)   ENSCING00000014285 (Ciona intestinalis)   txlng (Danio rerio)   CG5886 (Drosophila melanogaster)   txlng (Xenopus laevis)   ENSCAFG00000012620 (Canis familiaris)   (Compare orthologs)
UniProt Accession B4E0J6, Q9BZA5, Q2TAN5
Search EB-eye ENSG00000099749
Show more properties
Experimental Factors
Organism part

studied in E-MTAB-37, E-GEOD-17189, E-AFMX-5, E-TABM-34, E-GEOD-6573, ... (12 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-22152, E-GEOD-19639, E-GEOD-24147, E-GEOD-19480, ... (20 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
NCIH1930
1
E-MTAB-37
U87R4
1
E-GEOD-21570
HEC1B
1
E-MTAB-37
HCC-1428
1
E-GEOD-19639
SiHa
1
E-MTAB-37
336 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-20033, E-GEOD-5099, E-TABM-130, E-GEOD-1460, ... (22 experiments)

Factor Value U/D Experiments
M1 macrophage
1
E-GEOD-5099
secretory cell
1
E-GEOD-3998
naive T cell
1
E-GEOD-1460
cardiac myocyte
1
E-AFMX-5
human foreskin fibroblast
1
E-GEOD-18147
partially reprogrammed human induced pluripotent stem cell
1
E-GEOD-18147
33 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-GEOD-6872, E-MEXP-2069, E-GEOD-21912, ... (15 experiments)

Factor Value U/D Experiments
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
prostate carcinoma
2
E-MEXP-2034, E-GEOD-7307
myeloid leukemia
1
E-MTAB-37
mesothelioma
1
E-MTAB-37
T-cell lymphoma
1
E-MTAB-37
bronchogenic carcinoma
1
E-MTAB-37
38 more value(s).


Compound treatment

studied in E-TABM-868, E-GEOD-5099, E-MEXP-1958, E-GEOD-7307

Factor Value U/D Experiments
lipopolysaccharide
3
2
E-TABM-868, E-MEXP-1958
M-CSF
1
E-GEOD-5099
none
1
1
32
E-TABM-868, E-MEXP-1958
SDF
1
E-GEOD-7307


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Clinical history
studied in E-GEOD-22097, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-21610 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-5372, E-GEOD-20499, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Disease staging
studied in E-GEOD-19743, E-GEOD-3325

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-7578, E-GEOD-20847, E-MTAB-108

Genotype
studied in E-GEOD-3494, E-MEXP-149, E-GEOD-17476, E-MEXP-421, E-TABM-868, ... (7 experiments)

Growth condition
studied in E-GEOD-10315, E-MEXP-2146

Histology
studied in E-TABM-234, E-GEOD-21653

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-40, E-MEXP-2069, E-TABM-666, ... (23 experiments)

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-6532

Replicate
studied in E-GEOD-15811, E-GEOD-18791

sampleID
studied in E-GEOD-24283

Sex
studied in E-GEOD-22097, E-GEOD-1643, E-GEOD-19743, E-GEOD-20153, E-GEOD-19069, ... (20 experiments)

Stimulation
studied in E-GEOD-13909

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Processing time: 0.764 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM